Bi-Specific MAbS Market Report 2026

The bi-specific mabs market size has grown rapidly in recent years. It will grow from $11.64 billion in 2025 to $13.16 billion in 2026 at a compound annual growth rate (CAGR) of 13%. The growth in the historic period can be attributed to approval of first bsabs therapies, growing incidence of hematological cancers, early adoption of monoclonal antibodies, investment in oncology r&d, rise in hospital-based clinical trials.

The bi-specific mabs market size is expected to see rapid growth in the next few years. It will grow to $21.83 billion in 2030 at a compound annual growth rate (CAGR) of 13.5%. The growth in the forecast period can be attributed to advancements in gene and cell therapy integration, expansion of bsabs pipeline, increased r&d funding for rare diseases, growth in precision medicine adoption, emergence of novel bsabs delivery platforms. Major trends in the forecast period include expansion of tumor immunotherapy applications, development of multi-targeted bi-specific antibodies, growth in hemophilia and rare disease treatments, advancements in in vitro and in vivo platforms, rising collaborations between pharma and biotech firms.

The rising prevalence of cancer and other chronic diseases is expected to drive the growth of the bispecific monoclonal antibodies market over the forecast period. Bispecific monoclonal antibodies are designed to treat various cancers, infectious diseases, central nervous system disorders, and autoimmune diseases. They are considered more effective than traditional monoclonal antibodies (moAbs) because they can target two or more tumor antigens simultaneously, disrupting cancer progression. For example, in 2023, the Cancer Facts & Figures 2023 report by the American Cancer Society (ACS), a US-based voluntary health organization, estimated 609,820 cancer-related deaths in the USA. As a result, the increasing incidence of chronic diseases, including cancer, is expected to boost demand for bispecific mAbs to treat these conditions effectively.

Leading companies in the bispecific mAbs market are emphasizing technological innovations, such as CD20 × CD3 T-cell engaging bispecific antibodies, to address the growing need for effective, off-the-shelf immunotherapies in hematological malignancies with fixed-duration treatment regimens. A CD20 × CD3 bispecific antibody is engineered to bring T cells close to B cells by binding CD3 on T cells and CD20 on B cells, activating T-cell-mediated killing of malignant B cells. Unlike traditional monoclonal antibodies that target only B cells or T-cell checkpoints, this design harnesses immune effector function in a highly targeted manner. For instance, in June 2023, Roche AG, a Switzerland-based biopharmaceutical company, launched Columvi (glofitamab‑gxbm), a CD20×CD3 bispecific T-cell engager. Columvi has a 2:1 structural format (two CD20-binding domains and one CD3-binding domain), is administered as a fixed-duration (approximately 8.5-month) therapy, and is designed to deliver durable responses in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Its fixed-duration regimen offers the potential for a treatment-free period post-therapy, distinguishing it from continuous treatment approaches, and has demonstrated strong efficacy with manageable safety in clinical trials.

In June 2024, Johnson & Johnson, a US-based pharmaceutical company, acquired Proteologix, Inc. for $850 million. This strategic acquisition allows Johnson & Johnson to integrate two promising bispecific antibodies, PX-128 and PX-130, targeting key pathways in conditions such as atopic dermatitis and asthma. It strengthens J&J's immunology expertise while advancing its commitment to innovative care. The deal also provides access to additional bispecific antibody programs, enhancing treatment options for chronic conditions. Proteologix, Inc. is a US-based company focused on developing bispecific antibodies.

Major companies operating in the bi-specific mabs market are F. Hoffmann-La Roche AG, Amgen Inc, Johnson & Johnson, Kyowa Kirin, Zai Lab, Alphamab Oncology, Celldex Therapeutics, Biocon, EpimAb Biotherapeutics, ABL Bio, Takeda Pharmaceuticals, Innovent Biologics, Merck & Co Inc, Eli Lilly Company Inc., AbbVie Inc, Bayer AG, Pfizer Inc, Novartis AG, GlaxoSmithKline, AstraZeneca, Cytiva, Bristol Myers Squibb, AbCellera, BioMarin Pharmaceuticals, Sanofi S.A., Novo Nordisk A/S, Aspen Pharmacare, Baxter International.

North America was the largest region in the bi-specific MAbs market in 2025. The regions covered in the bi-specific mabs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the bi-specific mabs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the bi-specific mabs market by increasing the cost of importing raw materials and lab equipment critical for antibody development. These impacts are most pronounced in regions like north america and europe where manufacturing and r&d rely on imported biotech reagents. Hospital and research institute segments are directly affected due to higher procurement costs and project delays. However, tariffs have also encouraged some local manufacturing initiatives and innovation in cost-effective bsabs production methods, potentially benefiting long-term domestic capabilities.

The bi-specific mabs market research report is one of a series of new reports that provides bi-specific mabs market statistics, including bi-specific mabs industry global market size, regional shares, competitors with a bi-specific mabs market share, detailed bi-specific mabs market segments, market trends and opportunities, and any further data you may need to thrive in the bi-specific mabs industry. This bi-specific mabs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Bi-specific MAbs, or bispecific monoclonal antibodies, are antibodies with two binding sites, designed to attach to either two distinct antigens or two different epitopes. Unlike monoclonal antibodies (MoAbs), which lack certain clinical therapeutic effects, BsAbs offer a broad range of applications, including treatment of various diseases and tumor immunotherapy.

The primary types of bispecific antibodies include catumaxomab, blinatumomab, duligotumab, and SAR 156597. Catumaxomab is a rat-mouse hybrid monoclonal antibody used to treat malignant ascites, a condition found in patients with metastatic cancer. Different product forms, including in vivo and in vitro, are employed to treat cancer, autoimmune disorders, inflammatory conditions, infectious diseases, microbial infections, and more. Bispecific monoclonal antibodies are utilized by hospitals, research institutions, and other organizations.

The bi-specific MAbs or bispecific monoclonal antibodies market consists of sales of trifunctional antibodies, chemically linked Fabs, and bispecific T cell engagers. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.